BDENZA-OS
BDENZA-OS BDENZA-OS contains enzalutamide, an androgen receptor inhibitor used in the treatment of prostate cancer. It works by interfering with androgen-receptor signaling, thereby reducing the ability of testosterone and related hormones to stimulate prostate cancer cells.
BDR Pharmaceuticals introduced BDENZA as a 32 mg/mL oral solution, providing a liquid alternative to conventional enzalutamide tablets/capsules.
| Brand | BDENZA-OS |
| Storage Temperature | 20-25°C, in a dry place and protected from light |
| Prescription Needed | Yes |
| Composition | Enzalutamide |
| Strength | 32 mg/mL |
| Form | Oral Solution |
| Pack Size | 150 mL |
| Packaging | bottle |
| Country of Origin | Made In India |
| Manufacturer | BDR Pharmaceuticals Internationals Pvt. Ltd. |
BDENZA-OS
BDENZA-OS BDENZA-OS contains enzalutamide, an androgen receptor inhibitor used in the treatment of prostate cancer. It works by interfering with androgen-receptor signaling, thereby reducing the ability of testosterone and related hormones to stimulate prostate cancer cells.
BDR Pharmaceuticals introduced BDENZA as a 32 mg/mL oral solution, providing a liquid alternative to conventional enzalutamide tablets/capsules.
Related Products
-
-
Apanat 60
-
BDRelin Depot 3.75mg Injection
-
Denoci 120
-
Emzumab 150 mg
-
Erlocip 100
-
Erlocip 150
-
Erlonat 150
-
Fulvekast 250 mg/5 mL
-
Fulvenat 250 mg/5 mL
-
Fulveser 250 mg/5 mL
-
Fulviglen 250 mg/5 mL
-
LETS 2.5 mg
-
LeuGard 11.25 Depot Injection
-
Midostar 25mg
-
Mozifor 24 mg Injection
-
Ninlib 150 mg
-
Ninlib 200 mg
-
Nintib 100 MG Capsule
-
Nintib 150 MG Capsule
-
Nuparp 200 mg
-
Nuparp 250 mg
-
Nuparp 300 mg
-
Oncolet 2.5 mg
-
Perzea 420 mg Injection,
-
Phesgo 1200 mg / 600 mg
-
Phesgo 600 mg + 600 mg / 10 mL
-
Sorafekast 200 mg
-
Soranib 200
-
Sutinat 50
-
Temotero 100 mg
-
temotero 250 mg
-
Vivitra 440 Injection
-
Xgeva 120
-
zoladax 3.6 mg
-
Zoladex LA 10.8 mg
-
Zoldonat 4 mg Injection
-
Zyceva 100